Recent Advances in Antiviral Therapy for Chronic Hepatitis C
Joint Authors
Tamori, Akihiro
Enomoto, Masaru
Kawada, Norifumi
Source
Issue
Vol. 2016, Issue 2016 (31 Dec. 2016), pp.1-11, 11 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2016-01-31
Country of Publication
Egypt
No. of Pages
11
Main Subjects
Abstract EN
Hepatitis C virus (HCV) infection is a major worldwide health problem.
Chronic infection induces continuous inflammation in the liver, progression of hepatic fibrosis, eventual cirrhosis, and possible hepatocellular carcinoma.
Eradication of the virus is one of the most important treatment aims.
A number of promising new direct-acting antivirals (DAAs) have been developed over the past 10 years.
Due to their increased efficacy, safety, and tolerability, interferon-free oral therapies with DAAs have been approved for patients with HCV, including those with cirrhosis.
This review introduces the characteristics and results of recent clinical trials of several DAAs: NS3/4A protease inhibitors, NS5A inhibitors, and NS5B inhibitors.
DAA treatment failure and prognosis after DAA therapy are also discussed.
American Psychological Association (APA)
Tamori, Akihiro& Enomoto, Masaru& Kawada, Norifumi. 2016. Recent Advances in Antiviral Therapy for Chronic Hepatitis C. Mediators of Inflammation،Vol. 2016, no. 2016, pp.1-11.
https://search.emarefa.net/detail/BIM-1111170
Modern Language Association (MLA)
Tamori, Akihiro…[et al.]. Recent Advances in Antiviral Therapy for Chronic Hepatitis C. Mediators of Inflammation No. 2016 (2016), pp.1-11.
https://search.emarefa.net/detail/BIM-1111170
American Medical Association (AMA)
Tamori, Akihiro& Enomoto, Masaru& Kawada, Norifumi. Recent Advances in Antiviral Therapy for Chronic Hepatitis C. Mediators of Inflammation. 2016. Vol. 2016, no. 2016, pp.1-11.
https://search.emarefa.net/detail/BIM-1111170
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1111170